<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164212</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300004274</org_study_id>
    <nct_id>NCT04164212</nct_id>
  </id_info>
  <brief_title>Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection</brief_title>
  <official_title>Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to develop a nasal model for influenza infection using the live
      attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult
      volunteers in order to simulate influenza infection, and obtain nasal specimens to measure
      influenza virus and inflammatory/immune responses.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>influenza virus replication</measure>
    <time_frame>day 2</time_frame>
    <description>virus replication will be measured using RT-PCR and reported as genomic units, from samples obtained from nasal washing and nasal oropharyngeal swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>markers of inflammation</measure>
    <time_frame>change in inflammatory cytokines from baseline to day 2</time_frame>
    <description>a standard panel of inflammatory cytokines (Luminex Performance Human XL Cytokine Discovery Panel assay, R&amp;D Systems; results reported in pg/ml) will be measured in samples obtained from nasal washing and nasal oropharyngeal swabs</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>open label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flumist Quadrivalent Nasal Product</intervention_name>
    <description>FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer</description>
    <arm_group_label>open label</arm_group_label>
    <other_name>live attenuated influenza vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 18-49 years old,

          -  not yet received influenza vaccine for 2019-2020, and

          -  capable of giving signed informed consent.

        Exclusion Criteria:

          -  Immunocompromising condition (e.g. HIV/AIDS, chemotherapy, immune suppressing
             medications),

          -  active smoking within past 6 months,

          -  asthma, chronic lung/liver/kidney /neurologic/hematologic/metabolic
             disorders,cardiovascular disease (excluding isolated hypertension), diabetes mellitus,
             disease, congestive heart failure,

          -  pregnancy,

          -  current or recent (within the past month) upper/lower respiratory tract infection,
             chronic sinusitis/nasal allergies requiring frequent or daily therapy (including
             topical corticosteroids),

          -  prior adverse reaction to influenza vaccine,

          -  history of Guillain-Barre syndrome,

          -  egg allergy,

          -  close contact with an individual with severe immunodeficiency/immunosuppression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David LaFon, MD</last_name>
    <phone>2-5-934-0266</phone>
    <email>dlafon@uabmc.edu</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>David Lafon</investigator_full_name>
    <investigator_title>Clinical Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

